×
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   142.00 (+0.31%)
MSFT   263.93 (+0.41%)
META   166.45 (-1.03%)
GOOGL   2,247.44 (-0.79%)
AMZN   112.90 (-0.53%)
TSLA   686.99 (-1.75%)
NVDA   150.73 (+0.73%)
NIO   20.96 (-5.50%)
BABA   115.93 (-3.50%)
AMD   74.78 (-0.56%)
MU   57.86 (+1.99%)
CGC   2.64 (-2.58%)
T   21.12 (-0.24%)
GE   61.95 (-0.13%)
F   10.92 (-2.50%)
DIS   96.74 (-0.45%)
AMC   12.53 (-1.96%)
PFE   52.09 (+0.87%)
PYPL   74.00 (-0.54%)
NFLX   182.64 (-1.74%)
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   142.00 (+0.31%)
MSFT   263.93 (+0.41%)
META   166.45 (-1.03%)
GOOGL   2,247.44 (-0.79%)
AMZN   112.90 (-0.53%)
TSLA   686.99 (-1.75%)
NVDA   150.73 (+0.73%)
NIO   20.96 (-5.50%)
BABA   115.93 (-3.50%)
AMD   74.78 (-0.56%)
MU   57.86 (+1.99%)
CGC   2.64 (-2.58%)
T   21.12 (-0.24%)
GE   61.95 (-0.13%)
F   10.92 (-2.50%)
DIS   96.74 (-0.45%)
AMC   12.53 (-1.96%)
PFE   52.09 (+0.87%)
PYPL   74.00 (-0.54%)
NFLX   182.64 (-1.74%)
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   142.00 (+0.31%)
MSFT   263.93 (+0.41%)
META   166.45 (-1.03%)
GOOGL   2,247.44 (-0.79%)
AMZN   112.90 (-0.53%)
TSLA   686.99 (-1.75%)
NVDA   150.73 (+0.73%)
NIO   20.96 (-5.50%)
BABA   115.93 (-3.50%)
AMD   74.78 (-0.56%)
MU   57.86 (+1.99%)
CGC   2.64 (-2.58%)
T   21.12 (-0.24%)
GE   61.95 (-0.13%)
F   10.92 (-2.50%)
DIS   96.74 (-0.45%)
AMC   12.53 (-1.96%)
PFE   52.09 (+0.87%)
PYPL   74.00 (-0.54%)
NFLX   182.64 (-1.74%)
S&P 500   3,835.36 (+0.10%)
DOW   30,994.30 (+0.09%)
QQQ   286.80 (-0.06%)
AAPL   142.00 (+0.31%)
MSFT   263.93 (+0.41%)
META   166.45 (-1.03%)
GOOGL   2,247.44 (-0.79%)
AMZN   112.90 (-0.53%)
TSLA   686.99 (-1.75%)
NVDA   150.73 (+0.73%)
NIO   20.96 (-5.50%)
BABA   115.93 (-3.50%)
AMD   74.78 (-0.56%)
MU   57.86 (+1.99%)
CGC   2.64 (-2.58%)
T   21.12 (-0.24%)
GE   61.95 (-0.13%)
F   10.92 (-2.50%)
DIS   96.74 (-0.45%)
AMC   12.53 (-1.96%)
PFE   52.09 (+0.87%)
PYPL   74.00 (-0.54%)
NFLX   182.64 (-1.74%)

15 Healthcare Stocks that Analysts Love

Posted on Wednesday, July 6th, 2022 by MarketBeat Staff
There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems, and other healthcare stocks, it can be hard to identify which healthcare companies will outperform the market.

Fortunately, Wall Street's brightest minds have already done this for us. Every year, analysts issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firms are giving "strong-buy" and "buy" ratings to the same healthcare stock.

This slide show lists the 15 healthcare companies with the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

#1 - Mirum Pharmaceuticals (NASDAQ:MIRM)

Consensus Rating
Buy
Rating Score
3.2
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$51.80 (137.1% Upside)

Mirum Pharmaceuticals logoMirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
5/24/2022SVB LeerinkBoost Price TargetOutperform$50.00 ➝ $52.00
5/23/2022HC WainwrightBoost Price TargetBuy$64.00 ➝ $69.00
4/26/2022SVB LeerinkBoost Price TargetOutperform$46.00 ➝ $49.00
3/11/2022Raymond JamesBoost Price TargetStrong-Buy$70.00 ➝ $74.00
1/28/2022SVB LeerinkBoost Price TargetOutperform$42.00 ➝ $46.00
1/12/2022Raymond JamesBoost Price TargetStrong-Buy$69.00 ➝ $70.00
9/30/2021HC WainwrightBoost Price TargetAverage ➝ Buy$51.00 ➝ $64.00
9/30/2021SVB LeerinkBoost Price TargetOutperform$32.00 ➝ $41.00
9/30/2021Raymond JamesBoost Price TargetBuy ➝ Strong-Buy$51.00 ➝ $69.00
9/30/2021Robert W. BairdBoost Price TargetPositive ➝ Outperform$30.00 ➝ $34.00



#2 - AMN Healthcare Services (NYSE:AMN)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$137.60 (23.3% Upside)

AMN Healthcare Services logoAMN Healthcare Services, Inc provides healthcare workforce solutions and staffing services to hospitals and healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, rapid response nurse staffing and labor disruption, allied staffing, local staffing, and revenue cycle solutions.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/16/2022Credit Suisse GroupBoost Price TargetOutperform$120.00 ➝ $121.00
2/18/2022BenchmarkBoost Price TargetBuy$125.00 ➝ $140.00
2/18/2022Jefferies Financial GroupBoost Price TargetBuy$140.00 ➝ $170.00
11/17/2021Credit Suisse GroupBoost Price TargetOutperform$115.00 ➝ $139.00
11/8/2021BMO Capital MarketsBoost Price TargetOutperform$115.00 ➝ $127.00
8/31/2021Truist FinancialBoost Price TargetBuy$118.00 ➝ $130.00
8/10/2021Credit Suisse GroupBoost Price TargetOutperform$95.00 ➝ $115.00
8/9/2021BMO Capital MarketsBoost Price TargetOutperform$108.00 ➝ $115.00
6/18/2021Truist FinancialBoost Price TargetAverage ➝ Buy$102.00 ➝ $112.00
5/10/2021BMO Capital MarketsBoost Price TargetOutperform$86.00 ➝ $95.00



#3 - Alignment Healthcare (NASDAQ:ALHC)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$17.89 (38.7% Upside)

Alignment Healthcare logoAlignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, and Nevada.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/7/2022Morgan StanleyLower Price TargetOverweight$21.00 ➝ $18.00
5/26/2022Bank of AmericaUpgradeNeutral ➝ Buy$18.00 ➝ $14.00
5/5/2022William BlairReiterated RatingOutperform
4/4/2022SVB LeerinkInitiated CoverageOutperform$19.00
3/15/2022The Goldman Sachs GroupLower Price TargetBuy ➝ Buy$18.00 ➝ $16.00
3/7/2022The Goldman Sachs GroupLower Price TargetBuy$18.00 ➝ $16.00
3/7/2022Morgan StanleyLower Price TargetOverweight$25.00 ➝ $21.00
3/4/2022CowenLower Price TargetOutperform$24.00 ➝ $11.00
2/24/2022Piper SandlerLower Price TargetOverweight$25.00 ➝ $15.00
1/12/2022Raymond JamesLower Price TargetOutperform$30.00 ➝ $20.00



#4 - BridgeBio Pharma (NASDAQ:BBIO)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$31.00 (183.1% Upside)

BridgeBio Pharma logoBridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/15/2022The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$19.00 ➝ $21.00
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$24.00 ➝ $19.00
3/16/2022HC WainwrightLower Price TargetBuy$24.00 ➝ $22.00
3/11/2022JPMorgan Chase & Co.Lower Price TargetOverweight$21.00 ➝ $18.00
3/4/2022SVB LeerinkBoost Price TargetOutperform$24.00 ➝ $25.00
1/31/2022HC WainwrightReiterated RatingBuy$24.00
12/28/2021HC WainwrightLower Price TargetBuy$88.00 ➝ $24.00
12/27/2021SVB LeerinkLower Price TargetOutperform$66.00 ➝ $24.00
12/27/2021MizuhoLower Price TargetBuy$86.00 ➝ $25.00
11/19/2021SVB LeerinkLower Price TargetOutperform$68.00 ➝ $66.00



#5 - Catalyst Pharmaceuticals (NASDAQ:CPRX)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$10.92 (45.9% Upside)

Catalyst Pharmaceuticals logoCatalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
3/18/2022Truist FinancialReiterated RatingBuy$12.00
3/17/2022Piper SandlerBoost Price Target$8.00 ➝ $8.75
2/7/2022Piper SandlerBoost Price TargetOverweight ➝ Overweight$7.00 ➝ $8.00
2/7/2022HC WainwrightBoost Price TargetBuy$9.00 ➝ $12.00
10/1/2021HC WainwrightReiterated RatingBuy$9.00
9/14/2021HC WainwrightReiterated RatingBuy$9.00
8/15/2021Roth CapitalReiterated RatingBuy
8/10/2021Piper SandlerBoost Price TargetOverweight$5.50 ➝ $6.50
5/12/2021Cantor FitzgeraldBoost Price Target$8.00 ➝ $11.00
3/18/2021Roth CapitalBoost Price TargetBuy$6.50 ➝ $7.00



#6 - Roivant Sciences (NASDAQ:ROIV)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$12.00 (158.6% Upside)

Roivant Sciences logoRoivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/30/2022HC WainwrightReiterated RatingBuy$14.00
6/29/2022SVB LeerinkBoost Price TargetOutperform$6.00 ➝ $7.00
5/24/2022The Goldman Sachs GroupLower Price TargetBuy$15.00 ➝ $12.00
5/23/2022SVB LeerinkInitiated CoverageOutperform$6.00
4/29/2022Cantor FitzgeraldInitiated CoverageOverweight$15.00
12/15/2021The Goldman Sachs GroupInitiated CoverageBuy$15.00
12/5/2021SVB LeerinkReiterated RatingBuy
11/8/2021HC WainwrightInitiated CoverageBuy$14.00
11/1/2021SVB LeerinkInitiated CoverageOutperform$11.00
10/27/2021CitigroupInitiated CoverageBuy$11.00



#7 - BELLUS Health (NASDAQ:BLU)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$16.25 (57.6% Upside)

BELLUS Health logoBELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
2/24/2022HC WainwrightBoost Price TargetBuy$14.00 ➝ $16.00
12/13/2021BTIG ResearchBoost Price TargetBuy ➝ Buy$13.00 ➝ $18.00
12/13/2021Evercore ISIBoost Price TargetOutperform ➝ Outperform$12.00 ➝ $20.00
12/7/2021Royal Bank of CanadaBoost Price TargetOutperform$9.00 ➝ $11.00
11/16/2021HC WainwrightReiterated RatingBuy$14.00
10/18/2021Royal Bank of CanadaBoost Price TargetOutperform$8.00 ➝ $9.00
10/5/2021BTIG ResearchReiterated RatingBuy$13.00
9/26/2021BTIG ResearchReiterated RatingBuy$13.00
9/14/2021BTIG ResearchBoost Price TargetPositive ➝ Buy$9.00 ➝ $13.00
9/14/2021HC WainwrightReiterated RatingPositive ➝ Buy$10.00 ➝ $14.00



#8 - Compass Therapeutics (NASDAQ:CMPX)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$10.00 (266.3% Upside)

Compass Therapeutics logoCompass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/22/2022B. RileyReiterated RatingBuy
5/23/2022HC WainwrightReiterated RatingBuy$12.00
3/15/2022LADENBURG THALM/SH SHInitiated CoverageBuy$7.00
1/21/2022HC WainwrightInitiated CoverageBuy$11.00
1/18/2022B. RileyInitiated CoverageBuy$10.00
12/22/2021Raymond JamesInitiated CoverageOutperform$5.00
12/20/2021SVB LeerinkInitiated CoverageOutperform$12.00
12/15/2021WedbushInitiated CoverageOutperform$8.00
11/19/2021Roth CapitalInitiated CoverageBuy$15.00
11/16/2021HC WainwrightInitiated CoverageBuy$11.00



#9 - Quipt Home Medical (NASDAQ:QIPT)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$9.75 (107.0% Upside)

Quipt Home Medical logoQuipt Home Medical Corp. provides in-home medical equipment and supplies, and respiratory and durable medical equipment in the United States. The company also offers management of various chronic disease states focusing on patients with heart and pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/28/2022Raymond JamesSet Price TargetOutperform$9.00
2/16/2022Raymond JamesReiterated RatingOutperform$11.50
1/31/2022Raymond JamesSet Price TargetOutperform$9.00
12/17/2021Raymond JamesSet Price TargetOutperform$9.00
11/24/2021Raymond JamesSet Price TargetOutperform$9.00
11/17/2021Raymond JamesSet Price TargetOutperform$9.00
11/17/2021Stifel NicolausBoost Price TargetBuyC$12.40 ➝ C$12.75
11/9/2021Echelon Wealth PartnersReiterated RatingBuy
10/20/2021BenchmarkInitiated CoverageBuy$7.50
8/25/2021Raymond JamesReiterated RatingOutperform$9.00



#10 - BELLUS Health (TSE:BLU)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
C$15.75 (16.8% Upside)

BELLUS Health logoBELLUS Health Inc, a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
5/12/2022HC WainwrightReiterated RatingBuyC$16.00
2/24/2022HC WainwrightReiterated RatingBuyC$16.00
12/17/2021Royal Bank of CanadaBoost Price TargetOutperformC$11.00 ➝ C$14.00
12/13/2021BTIG ResearchInitiated CoverageBuyC$18.00
12/13/2021CowenReiterated RatingBuyC$15.00
11/15/2021BTIG ResearchReiterated RatingBuyC$13.00
11/12/2021HC WainwrightReiterated RatingBuyC$14.00
9/23/2021BTIG ResearchReiterated RatingBuyC$13.00
9/14/2021HC WainwrightReiterated RatingBuyC$14.00
9/13/2021BTIG ResearchInitiated CoverageBuyC$13.00



#11 - Equillium (NASDAQ:EQ)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$13.75 (584.1% Upside)

Equillium logoEquillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
5/23/2022HC WainwrightReiterated RatingBuy$15.00
5/9/2022Cantor FitzgeraldReiterated RatingOverweight
3/25/2022Stifel NicolausReiterated RatingBuy$12.00
3/24/2022HC WainwrightBoost Price TargetBuy$12.00 ➝ $15.00
1/5/2022SVB LeerinkLower Price TargetOutperform$18.00 ➝ $14.00
12/2/2021SVB LeerinkReiterated RatingOutperform
11/15/2021HC WainwrightReiterated RatingBuy$12.00
10/29/2021Stifel NicolausInitiated CoverageBuy
10/18/2021Cantor FitzgeraldReiterated RatingOverweight
9/15/2021Cantor FitzgeraldInitiated CoverageOverweight$14.00



#12 - ADC Therapeutics (NYSE:ADCT)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$40.50 (357.6% Upside)

ADC Therapeutics logoADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL).Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
5/23/2022HC WainwrightReiterated RatingBuy$54.00
4/12/2022Morgan StanleyBoost Price TargetOverweight$29.00 ➝ $30.00
3/4/2022HC WainwrightLower Price TargetBuy$55.00 ➝ $54.00
2/1/2022Morgan StanleyLower Price TargetOverweight$47.00 ➝ $29.00
11/8/2021Wolfe ResearchInitiated CoverageOutperform$44.00
11/4/2021HC WainwrightReiterated RatingBuy
11/3/2021Royal Bank of CanadaBoost Price TargetOutperform$33.00 ➝ $34.00
9/7/2021Morgan StanleyLower Price TargetOverweight$51.00 ➝ $47.00
8/10/2021HC WainwrightReiterated RatingBuy$55.00
8/9/2021Royal Bank of CanadaInitiated CoverageOutperform$33.00



#13 - Agiliti (NYSE:AGTI)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$26.17 (17.6% Upside)

Agiliti logoAgiliti, Inc provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services, including programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/6/2022BMO Capital MarketsBoost Price TargetOutperform$22.00 ➝ $28.00
3/11/2022The Goldman Sachs GroupLower Price TargetBuy ➝ Buy$32.00 ➝ $28.00
3/11/2022Raymond JamesLower Price TargetOutperform$30.00 ➝ $25.00
3/10/2022Morgan StanleyLower Price TargetOverweight$30.00 ➝ $24.00
3/9/2022CitigroupLower Price TargetBuy$28.00 ➝ $25.00
1/18/2022The Goldman Sachs GroupLower Price TargetBuy$37.00 ➝ $32.00
11/12/2021Raymond JamesBoost Price TargetOutperform$25.00 ➝ $30.00
11/10/2021KeyCorpBoost Price TargetOverweight$23.00 ➝ $27.00
9/17/2021Raymond JamesBoost Price TargetOutperform$22.50 ➝ $25.00
8/16/2021Morgan StanleyBoost Price TargetOverweight$21.00 ➝ $23.00



#14 - Xeris Biopharma (NASDAQ:XERS)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$6.13 (285.2% Upside)

Xeris Biopharma logoXeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/28/2022Craig HallumInitiated CoverageBuy$6.50
3/16/2022MizuhoLower Price TargetBuy$8.00 ➝ $6.00
3/11/2022HC WainwrightReiterated RatingBuy$8.00 ➝ $6.00
2/16/2022SVB LeerinkLower Price TargetOutperform$8.00 ➝ $6.00
12/31/2021SVB LeerinkBoost Price TargetOutperform$6.00 ➝ $8.00
12/31/2021HC WainwrightBoost Price TargetBuy$4.25 ➝ $5.40
12/16/2021SVB LeerinkReiterated RatingBuy$6.00
11/17/2021SVB LeerinkInitiated CoverageOutperform$6.00
11/11/2021HC WainwrightBoost Price TargetBuy$4.00 ➝ $4.25
10/29/2021HC WainwrightInitiated CoverageBuy$4.00



#15 - Arcutis Biotherapeutics (NASDAQ:ARQT)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$47.00 (107.5% Upside)

Arcutis Biotherapeutics logoArcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
6/7/2022Morgan StanleyBoost Price TargetOverweight$36.00 ➝ $39.00
4/7/2022MizuhoLower Price TargetBuy$58.00 ➝ $57.00
3/25/2022MizuhoReiterated RatingBuy$58.00
3/17/2022The Goldman Sachs GroupInitiated CoverageBuy$45.00
3/2/2022Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $37.00
2/23/2022Cantor FitzgeraldReiterated RatingOverweight
12/23/2021MizuhoReiterated RatingBuy$58.00
11/19/2021Morgan StanleyLower Price TargetOverweight$50.00 ➝ $35.00
10/1/2021MizuhoReiterated RatingBuy$58.00
7/16/2021Morgan StanleyLower Price TargetOverweight$52.00 ➝ $50.00



 




MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.